Predictive Oncology Inc (POAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Predictive Oncology Inc (POAI) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($-77.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See POAI equity to assets ratio to measure how much of total assets are equity-financed.
Predictive Oncology Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Predictive Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Predictive Oncology Inc to evaluate the quality of earnings relative to operating cash generation.
Predictive Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Predictive Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Devonian Health Group Inc
V:GSD
|
-0.675x |
|
Stern Groep N.V.
AS:PBH
|
0.907x |
|
Ortivus AB ser. B
ST:ORTI-B
|
-0.529x |
|
Canuc Resources Corp
V:CDA
|
-0.866x |
|
Sensei Biotherapeutics Inc
NASDAQ:SNSE
|
-0.056x |
|
Drillcon AB
ST:DRIL
|
0.073x |
|
Prostar Holdings Inc
V:MAPS
|
-0.535x |
|
TAG Oil Ltd.
V:TAO
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Predictive Oncology Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Predictive Oncology Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Predictive Oncology Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-202.61K | $-11.96 Million | 59.008x | +3800.73% |
| 2023-12-31 | $8.27 Million | $-13.19 Million | -1.595x | -180.55% |
| 2022-12-31 | $21.77 Million | $-12.37 Million | -0.568x | -87.45% |
| 2021-12-31 | $40.27 Million | $-12.21 Million | -0.303x | +93.46% |
| 2020-12-31 | $2.64 Million | $-12.26 Million | -4.638x | -496.57% |
| 2019-12-31 | $11.23 Million | $-8.73 Million | -0.778x | +99.21% |
| 2018-12-31 | $53.47K | $-5.29 Million | -98.890x | -5869.03% |
| 2017-12-31 | $2.69 Million | $-4.46 Million | -1.657x | +65.07% |
| 2016-12-31 | $923.68K | $-4.38 Million | -4.743x | -160.55% |
| 2015-12-31 | $4.11 Million | $-7.49 Million | -1.821x | -397.87% |
| 2014-12-31 | $-5.52 Million | $-3.37 Million | 0.611x | -48.98% |
| 2013-12-31 | $-3.22 Million | $-3.86 Million | 1.198x | +234.13% |
| 2012-12-31 | $-3.30 Million | $-1.18 Million | 0.358x | -45.61% |
| 2011-12-31 | $-2.70 Million | $-1.78 Million | 0.659x | +75.84% |
| 2010-12-31 | $-2.19 Million | $-820.68K | 0.375x | -32.99% |
| 2009-12-31 | $-2.34 Million | $-1.31 Million | 0.559x | -80.78% |
| 2008-12-31 | $-309.44K | $-900.53K | 2.910x | -- |
About Predictive Oncology Inc
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D cult… Read more